Halozyme director Posard sells 5,230 shares

A HALO director's reported sales were made under a written Rule 10b5-1 plan adopted June 15, 2026.

Rhea-AI Filing Summary

Halozyme Therapeutics, Inc. (HALO) director Matthew L. Posard sold 5,230 common shares on October 1, 2026, in four transactions: 730 shares at a weighted average price of $107.168 per share, 3,300 at $108.454, 1,100 at $109.569 and 100 at $110.040. The sales were made under a written Rule 10b5-1 trading plan adopted June 15, 2026.

Insider Trade Summary 10b5-1

Net Seller: 5,230 shares

Net Sell 4 txns

Insider Posard Matthew L.

Role Director

Sold 5,230 shs ($568K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	730	$107.168	$78K
Sale	Common Stock F1, F3	3,300	$108.454	$358K
Sale	Common Stock F1, F4	1,100	$109.569	$121K
Sale	Common Stock F1	100	$110.04	$11K

Holdings After Transaction: Common Stock — 53,609 shares (Direct)

Footnotes (4)

1. F1. The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1.
2. F2. Represents a weighted average sales price per share. The shares were sold at prices ranging from $106.930 to $107.660. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
3. F3. Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.990 to $108.930. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
4. F4. Represents a weighted average sales price per share. The shares were sold at prices ranging from $109.040 to $109.970. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Key Figures

Common shares sold at weighted average price: 730 shares at $107.168 per share Common shares sold at weighted average price: 3,300 shares at $108.454 per share Common shares sold at weighted average price: 1,100 shares at $109.569 per share +1 more

4 metrics

Common shares sold at weighted average price 730 shares at $107.168 per share October 1, 2026

Common shares sold at weighted average price 3,300 shares at $108.454 per share October 1, 2026

Common shares sold at weighted average price 1,100 shares at $109.569 per share October 1, 2026

Common shares sold at weighted average price 100 shares at $110.040 per share October 1, 2026

Key Terms

Rule 10b5-1, weighted average sales price per share, written trading plan

3 terms

Rule 10b5-1 regulatory

"in accordance with Rule 10b5-1"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

weighted average sales price per share financial

"Represents a weighted average sales price per share"

written trading plan financial

"made pursuant to a written trading plan"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many HALO shares did director Matthew L. Posard sell?

Matthew L. Posard sold 5,230 HALO common shares in four transactions on October 1, 2026: 730 shares at a weighted average price of $107.168 per share, 3,300 at $108.454, 1,100 at $109.569 and 100 at $110.040. The sales were made under a written Rule 10b5-1 trading plan adopted June 15, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/02/2026 - 04:38 PM Accepted by SEC EDGAR 10/02/2026 - 04:38 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Posard Matthew L.

(Last) (First) (Middle)

C/O HALOZYME THERAPEUTICS, INC.

12390 EL CAMINO REAL

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS, INC. [ HALO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/01/2026		S(1)		730	D	$107.168(2)	58,109	D
Common Stock	10/01/2026		S(1)		3,300	D	$108.454(3)	54,809	D
Common Stock	10/01/2026		S(1)		1,100	D	$109.569(4)	53,709	D
Common Stock	10/01/2026		S(1)		100	D	$110.04	53,609	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1.

2. Represents a weighted average sales price per share. The shares were sold at prices ranging from $106.930 to $107.660. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

3. Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.990 to $108.930. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

4. Represents a weighted average sales price per share. The shares were sold at prices ranging from $109.040 to $109.970. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Remarks:

	/s/ James R. Oehler, Attorney-in-Fact	10/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)